⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22371763 | 1.00 | — | — | |
| SCHEMBL22388811 | 0.82 | — | — | |
| SCHEMBL29816933 | 0.79 | HTR2C (0.45) | — | |
| SCHEMBL28415781 | 0.79 | HTR2C (0.45) | — | |
| SCHEMBL28414275 | 0.79 | HTR2C (0.45) | — | |
| SCHEMBL22444297 | 0.78 | FFAR2 (0.35) | — | |
| SCHEMBL22371723 | 0.78 | FFAR2 (0.35) | — | |
| SCHEMBL20819885 | 0.78 | FFAR2 (0.35) | — | |
| SCHEMBL20819892 | 0.78 | FFAR2 (0.35) | — | |
| SCHEMBL28408623 | 0.78 | FFAR2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681862-B1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-03 | — | — | US | disclosed |
| EP-3681862-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| CN-111164072-A | β -hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | 阿托基公司 | 2020-05-15 | — | — | CN | disclosed |
| WO-2019053425-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |